Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/7402
Title: Screening of natural products for therapeutic activity against solid tumors
Authors: El-Menshawi, Bassem S
Fayad, Walid
Mahmoud, Khaled
El-Hallouty, Salwa M
El-Manawaty, May
Keywords: Anticancer drugs;Cell-based assays;Natural products;High-throughput screening
Issue Date: Mar-2010
Publisher: CSIR
Abstract: Most of the currently used cancer therapeutics are natural products. These agents were generally discovered based on their toxicity to tumour cells using various bioassays. Although the exact mechanisms of action of the most commonly used cancer therapeutics such as anthracyclins, podophyllotoxins and camptothecin are incompletely understood, it is becoming increasingly clear that these agents often show complex modes of action at the cellular level, interacting with numerous targets. Such complex modes of action may be the very reason for clinical efficacy. For discovering new cytotoxic anticancer drugs sophisticated screening methods were used. The principles of such screening projects conducted, using collections of purified natural products or extracts from plants have been described. By performing simple but robust pre-screening tests such as the brine shrimp assay, bioactive extracts can be identified. Extracts (65) prepared from a collection of Egyptian plants were identified that showed cytotoxity on HepG2 cells. Interestingly, 22 (33%) of these raw extracts, induced > 2-fold induction of caspase-cleavage activity in a colon carcinoma cell line, consistent with induction of apoptosis. Only a fraction of the diversity of the biosphere has been tested for biological activity and novel cancer therapeutics remains to be discovered.
Page(s): 258-264
URI: http://hdl.handle.net/123456789/7402
ISSN: 0975-1009 (Online); 0019-5189 (Print)
Appears in Collections:IJEB Vol.48(03) [March 2010]

Files in This Item:
File Description SizeFormat 
IJEB 48(3) 258-264.pdf174.09 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.